What does the UK Life Sciences Strategy mean for the pharma and biotech sector?

Edward Jones, a policy and communications consultant at independent London-based strategic communications firm GK Strategy, considers the opportunities presented by the UK government's ambitious new vision in an Expert View piece.

The life sciences industry is one of the dominant sectors of the UK economy, generating £64 billion ($89.6 billion) turnover every year and employing more than 233,000 scientists and staff1.

With leaked UK government reports anticipating a negative economic impact from Brexit, the government is keen to utilize Britain’s world-leading research to support the high-skilled life sciences sector and ensure economic growth in post-Brexit Britain. To achieve this and to get better treatments to patients faster, the government unveiled its Life Sciences Industrial Strategy at the end of last year2.